Benedikt Timmerman, PhD, MBA • Founder, Chairman of the Management Board and Chief Executive Officer.
Benedikt had acquired more than ten years of international experience in life sciences companies before he co-founded the Company with Ludovic de Meeus d'Argenteuil in 2001 under the name of BT Pharma. Initially, he ran the Company as sole Managing Director, then from 2007 as Chairman of the Management Board.
Prior to founding the Company, Benedikt was Biotechnology Director at Sandos Seeds (1991-1994), Senior R&D Director at Novartis Seeds from 1994 to 2000, member of the European Executive Committee of the same group from 1995 to 2000 and member of the "licenses and acquisitions" group at Novartis Agribusiness from 1997 to 2000.
Benedikt obtained a doctorate in sciences at the University of Ghent in Belgium in 1986 as well as MBA at INSEAD in France in 1991.
Martin Koch, M.Sc. Eng, MBA, Member of the Management Board and Chief Financial and Administrative Officer.
After several years of industrial experience at Nestlé in France, Martin joined the pharmaceutical industry upon completing his Master of Business Administration (MBA) at INSEAD in France in 1991. He then acquired more than 20 years of international experience in various management roles, mainly in the financial sector.
In particular, Martin participated, as Financial Director Europe at Elan Group, in the sale of Elan's European commercial activities to Zeneus Pharma Group where he served as the European controller from 2004 to 2005.
Martin joined the Company as Chief Financial and Administrative Officer in September 2007.
Before receiving his MBA, Martin graduated in agri-engineering from the Institut National Agronomique Paris-Grignon (INAPG) in 1984. Martin was appointed CEO in July 2015, during Benedikt's temporary leave of absence following multiple lower limb fractures.
Sophie Olivier, MD, M.Sc., Chief Medical Officer.
Formerly an Intern and Clinical Director at Hôpitaux de Marseille (1986-1996), Sophie joined the pharmaceutical industry in 1996. Between 1996 and 2009, she performed various roles in Medical Affairs and then Clinical Research at Wyeth, initially in the French subsidiary then in the USA as Senior Director Women's Health & Bone Repair, Worldwide Project Leader Clinical Research & Development. In these roles, Sophie supervised the clinical development of a range of molecules in the field or contraception, menopause, and osteoporosis. In 2009, Sophie joined the European Medicines Agency (London, UK) as Scientific Coordinator in pediatrics in charge of evaluating pediatric programs, particularly for vaccines.
Sophie joined the Company as Chief Medical Officer in March 2014.
She obtained an MD with a specialization in gynecology/obstetrics in 1992, and an M.Sc. in Biology and Reproduction in 1990.
Rémi Palmentier, PhD, Chief Scientific Officer.
With over 18 years of biotech and pharmaceutical industry experience, Dr. Palmantier brings to Genticel an in-depth expertise in therapeutic cancer vaccines as well as in other chronic diseases. He joins Genticel from GSK Vaccines, where he was most recently Senior Director, R&D, for the global portfolio of immunotherapies for chronic diseases. Formerly, Dr. Palmantier was Head of Cancer Preclinical Immunotherapies at GSK Biologicals (Canada), and was deeply involved in evaluating external opportunities for licensing to build a portfolio of immunotherapeutic candidates. He started his career with GSK Biologicals in 1997 and held various scientific positions in the Therapeutic Cancer Vaccine Program. Dr. Palmantier has authored multiple scientific publications and is the inventor of over 10 patents with worldwide coverage. He holds a PhD in Immunology from the University of Laval (Canada), and completed a post-doctoral fellowship at the Laboratory of Molecular Carcinogenesis, National Institute of Environmental Health Sciences, Research Triangle Park, NC, USA.